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ultrasoundCurrent surveillance for metal-on-metal hip resurfacing (MoMHR) patients is not evidence based. This study
established changes that occurred in 152 asymptomaticMoMHRsusing repeat ultrasound andpatient-reported out-
comes. Factors associated with (1) ultrasound progression and (2) developing new pseudotumors were analyzed.
Patients underwent repeat assessments 4.3 years later. Ultrasound progression was observed in 19% (n = 29),
with 10% (n = 15) developing new pseudotumors. Key predictors of ultrasound progression included high blood
cobalt (P= .00013) and chromium (P= .00065), and high initial ultrasound grade (P= .003) and volume (P=
.036). No asymptomaticMoMHRswith initially normalmetal ions (b2 μg/L) andnormal ultrasounds (33%of cohort)
developed new pseudotumors. This patient subgroup does not require repeat follow-up within 5 years.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Numerous metal-on-metal (MoM) hip arthroplasty designs have
experienced high failure rates due to pseudotumors [1,2]. Patients
developing these problems often require revision surgery. As lesions
can be destructive with signiﬁcant bone and muscle damage, outcomes
after revision can be poor [3,4]. To identify patients with pseudotumors
early, regulatory authorities have published guidance regarding the
regular follow-up of MoM hip patients [5–7].
Presently, there is no consensus on how to follow up asymptomatic
MoM hip resurfacing (MoMHR) patients, with this patient subgroup
being the most difﬁcult to manage clinically [8,9]. European guidance
recommends annual follow-up with radiographs and blood metal ions
in these patients. However, the US Food and Drug Administration
guidance recommends annual clinical review, whereas the Medical
and Healthcare Products Regulatory Agency in the United Kingdom
recommend reviewing asymptomatic MoMHR patients according to
local protocol. Recent work has demonstrated that worldwide MoM
hip follow-up guidance is neither evidence based nor ﬁnancially
sustainable, with most protocols lacking the sensitivity to detect
asymptomatic pseudotumors [10].dpotential or pertinent conﬂicts
direct or indirect, institutional
eld which may be perceived to
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. This is an open access article underMost MoMHR patients remain asymptomatic and do not develop
pseudotumors [11,12]. However, a small but signiﬁcant number of
asymptomatic patients do develop pseudotumors [8,9,13], and it is im-
portant to identify these individuals early in order to prevent bone and
soft tissue damage. At present, there is no clear guidance as towhich pa-
rameters should be used to distinguish asymptomatic MoMHR patients
who can be safely discharged and need not be subjected to repeated in-
vestigations from those asymptomatic MoMHR patients who need
monitoring. Decisions regarding which asymptomatic MoMHR patients
require monitoring, at what intervals, and how frequently such follow-
up should be repeated require well-designed prospective longitudinal
cohort studies. At present, very few such studies exist involving
MoMHR patients, with most reporting on serial magnetic resonance
imaging (MRI) at short-term follow-up in small cohorts [14,15]. Ultra-
sound is another commonly used and recommended modality for
cross-sectional imaging in MoM hip patients [5,16]. It has many advan-
tages overMRI: it is cheaper, faster to perform, andnot affected bymetal
artifact. Furthermore, ultrasound is sensitive when screening for
pseudotumors [16] with results comparable to MRI [17], and recent
work suggests that ultrasound has a role in the surveillance of asymp-
tomatic pseudotumors [18].
This article reports on a prospective cohort of 152 asymptomatic
MoMHRs who were comprehensively assessed between 2007 and
2008 [8]. Ultrasound and patient-reported outcomes were repeated at
a mean of 4.3 years since initial assessment and at a mean of 8.2 years
since primary MoMHR. The present study aimed to assess factors asso-
ciated with (1) ultrasound ﬁnding progression and (2) developing new
pseudotumors. This information will assist in risk stratifying patients,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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asymptomatic MoMHR patients.
Patients and Methods
Between 2007 and 2008, we performed an ethically approved pro-
spective cohort study involving 201 asymptomatic MoMHRs in 158 pa-
tients (mean age, 56.0 years; 61% male) [8]. This study was designed to
determine the prevalence of pseudotumors in asymptomatic patients
after MoMHR, given little was known about this clinical entity at the
time. Therefore, asymptomatic MoMHR patients participating in this
initial study were assessed at variable time points from their index
arthroplasty, although all patients were assessed at a minimum of 3
years from MoMHR. In 2007/2008, all patients completed an Oxford
Hip Score (OHS) and theUniversity of California, Los Angeles (UCLA) ac-
tivity score questionnaire. Patients were also investigated using hip ra-
diographs, blood metal ions, and hip ultrasound. Details about this
initial patient cohort and the investigations performed have been de-
scribed previously [8]. In 2012/2013, these patients underwent repeat
hip ultrasound examination and completed a further OHS and UCLA
score questionnaire. The OHS was scored from 0 (worst outcome) to
48 points (best outcome) [19], and the UCLA activity scores were from
1 (wholly inactive) to 10 (regular participation in impact sports) [20].
Repeat investigations were performed in 152 of the asymptomatic
MoMHRs (122 patients) at a mean of 4.3 years (range, 3.2-5.0 years)
from the initial assessment (Table 1). The mean duration from MoMHR
implantation to ﬁnal follow-up was 8.2 years (range, 6.2-12.4 years).
Forty-nine MoMHRs in 36 patients from the initial cohort were not re-
cruited to the present study for the following reasons: death (4 hips in 3
patients), revision to a total hip arthroplasty (16 hips in 13 patients), de-
clined to participate, or did not attend scheduled ultrasound appoint-
ments (29 hips in 20 patients). The demographics for these 49 MoMHRs
as well as the results of their initial assessment are summarized (Table 2).
Mean time from initial assessment to revision for the 16 revised
MoMHRs was 2.5 years (range, 0.4-4.4 years), and the mean time
from primary MoMHR to revision was 6.6 years (range, 3.1-9.4 years).Table 1
Summary of the Study Cohort.
152 Hips in 122 Patients
Gender, male/female 99 (65%)/53 (35%)
Age at ﬁrst ultrasound (y), mean (range) 60.7 (33.3 to 74.7)
Patients with unilateral or bilateral MoM hips,
unilateral/bilateral
92 (75%)/30 (25%)
Hip resurfacing design
Birmingham Hip Resurfacing
(Smith & Nephew, Warwick, UK)
82 (54%)
Conserve Plus (Wright Medical, Memphis, TN) 64 (42%)
Recap (Biomet, Bridgend, UK) 6 (4%)
Time between hip resurfacing and ﬁrst ultrasound (y),
mean (range)
3.9 (3.0 to 7.4)
Time interval between repeat ultrasounds (y),
mean (range)
4.3 (3.2 to 5.0)
Acetabular component position
Inclination (°), mean (range) 46.2 (21.3 to 65.5)
Anteversion (°), mean (range) 15.9 (2.0 to 33.0)
Blood metal ion concentration (μg/L), median (IQR)
Cobalt 2.3 (1.5 to 4.2)
Chromium 2.4 (1.3 to 4.9)
OHS (0-48 scale)
Median (IQR)
- 2007/2008 score 47.0 (45.0 to 48.0)
- 2012/2013 score 46.0 (42.8 to 48.0)
Mean (range)
- Change in score −0.9 (−17 to 7)
UCLA score (1-10 scale), mean (range)
- 2007/2008 score 7.2 (3 to 10)
- 2012/2013 score 7.2 (2 to 10)
- Change in score 0.1 (−4 to 5)
Hips with pseudotumors revised after repeat ultrasound 4 (3%)The indications for the 16 MoMHR revisions were symptomatic
pseudotumor (n = 14), dislocation (n = 1), and femoral component
loosening (n = 1). All hips were revised to a non-MoM bearing. The
14 revisions for symptomatic pseudotumor all had blood metal ions
above 2 μg/L and abnormal ultrasound imaging when assessed in the
initial study (Table 2). The mean pseudotumor volume on initial ultra-
soundwas 48.5 cm3 (6.8-135.2 cm3), with 50% (n= 7) cystic in nature,
36% (n = 5) mixed, and 14% (n = 2) solid lesions. All pseudotumors
were conﬁrmed both intraoperatively and on histopathologic examina-
tion. At latest follow-up, themean postrevision OHSwas 31.4 (range, 11-
48). Fifteen revisedMoMHRs remain in situ, with 1 pseudotumor patient
subsequently undergoing re-revision for recurrent dislocation within 8
months of the revision procedure.
The same experienced musculoskeletal radiologist performed all
ultrasound examinations in the initial study and the 2012 study. Ultra-
sound imaging (Sonoline Antares; SiemensMedical Solutions, Malvern,
PA) was performed following verbal patient consent using a standard
technique, which encompasses a systematic approach to assess the
anterior, medial, lateral, and posterior hip regions. This examination
technique is recommended by the European Society of Skeletal Radio-
logy and is widely used for examining the hip joint [21], and allows
for the assessment of a range of pathologies associated with hip
arthroplasty [22].
The radiologist graded all scans and measured volumes of any le-
sions present. In each instance, the radiologist was blinded to all clinical
information. Each ultrasound scan was assigned to one of four grades:
(1) normal, (2) bursa (psoas bursa, trochanteric bursa/thickening),
(3) pathological effusion, and (4) pseudotumor. A small amount of
intra-articular ﬂuid was considered normal, but when the depth of
ﬂuid exceeded 15 mm at the anterior joint line, this was classiﬁed as a
pathological effusion. Simple ﬂuid collections in the anatomical psoas
or trochanteric bursa were classiﬁed as such, but complex bursal collec-
tionswith evidence of communicationwith the hip jointwere classiﬁed
as pseudotumors. A pseudotumor was deﬁned as a cystic, solid, or
mixed mass with evidence of communication with, but extending be-
yond the conﬁnes of, the anatomical hip joint. When lesions were pres-
ent, the volume (product of the maximum recorded dimension in each
of three orthogonal planes in centimeters), consistency (solid, cystic, or
mixed), and location were recorded for each lesion.
Outcomes of interest were (1) the proportion of MoMHRs with pro-
gression of ultrasound ﬁndings between repeat scans and (2) the pro-
portion of MoMHRs developing new pseudotumors between repeat
ultrasounds. Hips were considered to have progression of ultrasound
ﬁndings between repeat scans if at least one of the following criteria
were present: (1) an increase in ultrasound scan grade, (2) an increase
in lesion volume but no change in ultrasound grade, (3) change in
pseudotumor consistency from liquid to solid, and/or (4) need for revi-
sion surgery. Progression of pseudotumors to a solid consistency has
been associated with adverse outcomes [3,23]; therefore, this change
was deemed to be clinically signiﬁcant. All MoMHRs not meeting
these criteria after repeat ultrasound examination were considered to
have no evidence of progression.
Statistical analysis
All statistical analyses were performed using the R library [24]. Ei-
ther the median and interquartile range (IQR) or the mean and range
were used depending on data distribution. For paired analyses, change
in volume between ultrasound scans was assessed using a paired
t test, and change in grade between scans was assessed using a
Wilcoxon signed rank test. To assess factors associatedwith progression
of ultrasound ﬁndings and the development of new pseudotumors, sta-
tistical testswere chosen to reﬂect the exposure variable and data distri-
bution. These included unpaired t tests (age, acetabular inclination and
anteversion, time from primary MoMHR to ﬁrst scan, time between
repeat scans, change in OHS, UCLA score, initial lesion volume), the
Table 2
Summary of 2007-2008 Data for 49 MoMHRs in 36 Patients That Were Excluded From the 2012 Study.
Revised Before 2012 (n = 16) Died (n = 4) Declined to Participate (n = 29)
Gender, male/female 2 (12%)/14 (88%) 4 (100%)/0 (0%) 20 (69%)/9 (31%)
Age at 2007/2008 ultrasound (y), mean (range) 59.2 (39.2-73.1) 66.4 (61.6-70.2) 60.6 (40.8-73.8)
Patients with unilateral or bilateral MoM hips, unilateral/bilateral 10 (77%)/3 (23%) 2 (67%)/1 (33%) 11 (55%)/9 (45%)
Hip resurfacing design
BHR 10 (63%) 1 (25%) 18 (62%)
Conserve 4 (25%) 3 (75%) 11 (38%)
Recap 2 (12%) 0 (%) 0 (0%)
Time between hip resurfacing and 2007/2008 ultrasound (y), mean (range) 4.1 (3.0-5.8) 3.9 (3.4-5.2) 4.7 (3.0 to 7.1)
Acetabular component position
Inclination (°), mean (range) 47.0 (34.7-55.3) 39.4 (37.9-40.8) 45.5 (30.1-64.0)
Anteversion (°), mean (range) 16.5 (5.1-34.3) 16.2 (14.9-17.5) 13.9 (7.2-20.8)
Blood metal ion concentration (μg/L), median (IQR)
Co 6.3 (4.7-13.3)a 0.9 (0.9-1.0) 1.6 (1.3-2.7)
Cr 7.1 (3.8-19.6)a 1.3 (1.1-1.5) 1.5 (1.2-2.4)
Ultrasound grade 2007/2008
1 2 (13%) 2 (50%) 26 (90%)
2 0 (0%) 2 (50%) 3 (10%)
3 1 (6%) 0 (0%) 0 (0%)
4 13 (81%) 0 (0%) 0 (0%)
OHS (0-48 scale), 2007/2008, median (IQR) 41.0 (35.0-46.5) 48.0 (48.0-48.0) 47.0 (44.0-48.0)
UCLA score (1-10 scale), 2007/2008, mean (range) 5.6 (3-8) 8.5 (7-10) 7.3 (1-10)
BHR, Birmingham Hip Resurfacing; Co, cobalt; Cr = chromium.
a For the 14 hip revisions performed for symptomatic pseudotumor, bloodmetal ion concentrations in 2007/2008were as follows:median (IQR): cobalt= 10.7 μg/L (5.9-14.3 μg/L) and
chromium= 11.6 μg/L (6.3-24.4 μg/L), and mean (range): cobalt = 14.5 μg/L (2.9-64.1 μg/L) and chromium= 15.8 μg/L (2.1-45.2 μg/L).
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tions), and χ2 test with Yates correction (gender, MoMHR design, bila-
teral MoMHRs, grade of ﬁrst ultrasound scan). The level of signiﬁcance
was set at P b .05. Diagnostic test characteristics with respective 95%
conﬁdence intervals were calculated for various clinical scenarios
relating to the results of the initial investigations (ie, normal initial
ultrasound with low blood metal ions, normal initial ultrasound alone,
and low blood metal ions alone).
Results
Change in Grade and Volume Between Repeat Ultrasound Scans
Changes in grade that occurred between repeat ultrasound scans are
summarized (Table 3). An increase in grade between scans was seen in
17% (n= 25) of hips, 80% (n= 122) had no grade change, and 3% (n=
5) had a decrease in grade. Therewas a signiﬁcant increase in ultrasound
grade between repeat scans (P = .00018). The mean change in lesion
volume between scans for all 152 MoMHRs was an increase of 5.9 cm3
by the second scan (range,−21.8 to 392 cm3), which was signiﬁcant
(P= .0058). For each initial ultrasound scan grade, the risk of any pro-
gression in ﬁndings and the risk of developing new pseudotumors 3.2
to 5.0 years later were as follows, respectively: grade 1, 12% (13/110)
and 4% (4/110); grade 2, 39% (9/23) and 35% (8/23); grade 3, 43% (3/
7) and 43% (3/7); and grade 4, 33% (4/12) and not applicable.
Progression of Ultrasound Findings
Evidence of any progression in ﬁndings between repeat scans oc-
curred in 19% (n = 29) of hips. Of those with progression, 25 hips hadTable 3
Change in Ultrasound Grade Between Scans in 152 MoMHRs.
Ultrasound Grade
2007/2008
Total number of
hips (%)
Ultrasound Grade 2012/2013
1 2 3 4
Total number hips (%) 152 (100) 102 (67) 17 (11) 6 (4) 27 (18)
1 110 (72) 97 (64) 6 (4) 3 (2) 4 (3)
2 23 (15) 3 (2) 11 (7) 1 (1) 8 (5)
3 7 (5) 2 (1) 0 (0) 2 (1) 3 (2)
4 12 (8) 0 (0) 0 (0) 0 (0) 12 (8)grade increases, with the other 4 hips having an increase in lesion
volume (increase of between 19 and 286 cm3) with no grade increase.
One of these 29 hips also experienced pseudotumor progression from
liquid to solid. Four of these 29 hips have been revised to date. The
remaining 81% (n = 123) of MoMHRs in this cohort had no evidence
of progression between repeat ultrasounds. Five factors were signiﬁ-
cantly associated with progression of ultrasound ﬁndings between
repeat scans (Table 4): high blood cobalt concentration (P = .00013),
high blood chromium concentration (P = .00065), decrease in OHS,
(P = .043), high initial ultrasound scan volume (P = .036), and high
initial ultrasound scan grade (P= .003).
Development of New Pseudotumors
New pseudotumors developed in 10% (n = 15) of the cohort
(Table 3). The median volume of these new lesions was 18.0 cm3
(IQR, 6.8-35.6 cm3). Median (IQR) cobalt and chromium concentrations
for this subgroup were 3.8 μg/L (2.6 μg/L to 9.8 μg/L) and 3.9 μg/L (2.4-
8.2 μg/L), respectively. Themean (range) acetabular component inclina-
tion and anteversion for MoMHRs developing new pseudotumors were
44.7° (range, 27.8°-57.0°) and 15.0° (range, 2.7°-30.3°), respectively.
Analysis demonstrated that high blood cobalt concentration (P =
.006) and high blood chromium concentration (P= .023) were signiﬁ-
cantly associated with developing new pseudotumors. All other factors
analyzed in Table 4 were found to be nonsigniﬁcant (P values ranging
from .074 to .955) for developing new pseudotumors.
The results of the initial assessment (2007/2008) in hips with a
pseudotumor on ultrasound in 2012 (n = 27) were compared with
the results in hips revised for symptomatic pseudotumor (n = 14).
Hips revised for pseudotumor had signiﬁcantly higher blood cobalt
(P = .02) and chromium (P = .02) concentrations, and signiﬁcantly
lower OHS (P= .007) and UCLA (P= .003) scores.
Diagnostic Test Characteristics for Clinical Scenarios
In light of the factors signiﬁcantly associated with progression of ul-
trasound ﬁndings between repeat scans and those factors associated
with developing new pseudotumors, three clinical scenarios were
formulated and the diagnostic test characteristics for these scenarios
were assessed. The optimal diagnostic test characteristics for identifying
both MoMHRs with no evidence of progression of ultrasound ﬁndings
Table 4
Factors Associated With Progression of Ultrasound Findings Between Repeat Imaging.
Factor Hips With Progression (n = 29) Hips Without Progression (n = 123) P
Gender
Female 12 (41%) 41 (33%) .548
Male 17 (59%) 82 (67%)
Age at ﬁrst ultrasound (y), mean (range) 62.2 (52.7-74.7) 60.3 (33.3-73.1) .237
Unilateral or bilateral MoM hips
Bilateral 11 (38%) 49 (40%) 1.00
Unilateral 18 (62%) 74 (60%)
Hip resurfacing design
BHR 14 (48%) 68 (55%) .756
Conserve 14 (48%) 50 (41%)
Recap 1 (4%) 5 (4%)
Time between hip resurfacing and ﬁrst ultrasound (y), mean (range) 3.9 (3.0-7.4) 3.9 (3.0-7.0) .947
Time interval between repeat ultrasounds (y), mean (range) 4.2 (3.2-5.0) 4.4 (3.2-5.0) .080
Acetabular inclination (°), mean (range) 47.2 (27.8-62.6) 46.0 (21.3-65.5) .501
Acetabular anteversion (°), mean (range) 14.8 (2.7-32.0) 15.3 (2.0-33.0) .783
Blood cobalt concentration (μg/L), median (IQR) 3.8 (2.6-6.3) 2.0 (1.3-3.6) .00013a
Blood chromium concentration (μg/L), median (IQR) 4.1 (2.5-7.5) 2.0 (1.2-3.9) .00065a
Initial OHS (0-48 scale), median (IQR) 47.0 (45.0-48.0) 47.0 (45.0-48.0) .775
Change in OHS, mean (range) −3.6 (−10 to 5) −0.3 (−2 to 7) .043a
Initial UCLA score (1-10 scale), mean (range) 6.9 (4-9) 7.3 (3-10) .208
Change in UCLA score, mean (range) −0.1 (−3 to 4) 0.1 (−4 to 5) .534
Initial scan volume (cm3), mean (range) 5.9 (0-60.0) 1.4 (0-100.0) .036a
Initial scan grade
1 13 (45%) 97 (79%) .003a
2 9 (31%) 14 (11%)
3 3 (10%) 4 (3%)
4 4 (14%) 8 (7%)
a Statistically signiﬁcant (P b .05).
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were obtained for asymptomatic MoMHRs with low initial blood cobalt
and chromium levels (b2 μg/L) and normal initial ultrasound scans
(grade 1) (n=50; 33% of current cohort). The diagnostic test characteris-
tics for having no evidence of progression of ultrasoundﬁndings on repeat
examination for this subgroup were as follows: sensitivity, 40%; speciﬁci-
ty, 97%; positive predictive value (PPV), 98%; negative predictive value
(NPV), 27%; positive likelihood ratio (LR+), 11.6; and negative likelihood
ratio (LR−), 0.6. Thediagnostic test characteristics for not developingnew
pseudotumors in this subgroup were as follows: sensitivity, 37%;
speciﬁcity, 100%; PPV, 100%; NPV, 15%; LR+, inﬁnity; and LR− 0.6.Discussion
Although the management of asymptomatic MoMHR patients has
proved to be difﬁcult, little evidence is available regarding the serial
cross-sectional imaging changes that occur in relation to these implants
[14,15,18]. Previous studies performing serial imaging in MoMHR
patients have involved small cohorts (4-53 hips) with short-term
follow-up between repeat imaging (mean of 0.7-2.2 years), and also
have not uniformly included asymptomatic patients only [14,15,18].Table 5
Diagnostic Test Characteristics for Asymptomatic MoMHRs Having no Evidence of Pro-
gression of Ultrasound Findings on Repeat Examination for 3 Different Clinical Scenarios.
Normal Initial Ultrasound
and Initial Blood Metal
Ions b2 μg/L
Normal Initial
Ultrasound
Alone
Initial Blood Metal
Ions b2 μg/L Alone
No. of hips
(% of cohort)
50 (33) 110 (72) 62 (41)
Sensitivity 40 (31-49) 79 (70-85) 48 (39-57)
Speciﬁcity 97 (80-100) 55 (36-73) 90 (72-97)
PPV 98 (88-100) 88 (80-93) 95 (85-99)
NPV 27 (19-37) 38 (24-54) 29 (20-40)
LR+ 11.6 (1.6-80.2) 1.8 (1.2-2.7) 4.6 (1.6-13.8)
LR− 0.6 (0.5-0.7) 0.4 (0.3-0.6) 0.6 (0.5-0.7)
All diagnostic test characteristic values are provided as percentages with 95% conﬁdence
intervals provided in brackets.The present study represents the largest cohort of MoMHR patients
(n = 152) investigated with repeat ultrasound within 5 years of initial
assessment. Although there were signiﬁcant increases in ultrasound
grade and volume between repeat scans, it was observed that asymp-
tomatic MoMHR patients with normal initial blood metal ion levels
(b2 μg/L) and normal ultrasound imaging had very little risk of progres-
sion of ultrasound ﬁndings, and no risk of developing new
pseudotumors within 5 years of initial assessment. These ﬁndings are
of clinical importance to guide the follow-up of asymptomatic MoMHR
patients, given that current protocols are not evidence based, with
most lacking the sensitivity to detect asymptomatic pseudotumors [10].
Serial ultrasound imaging was effective for identifying the develop-
ment and progression of abnormalities around MoMHRs, including
pseudotumors. This suggests that ultrasound is a useful clinical tool
for the surveillance of MoMHR patients, and supports the ﬁndings of a
smaller longitudinal study which observed ultrasound was effective in
the short-term for monitoring the natural history of asymptomatic
pseudotumors around MoM hips [18]. In the present study, the risk of
any progression in ultrasound ﬁndings (33%-43%) and the risk of
developing new pseudotumors (35%-43%) in MoMHRs with an
abnormal initial ultrasound (grades 2, 3, or 4) were higher than those
in hips with normal (grade 1) initial scans (12% risk of progressionTable 6
Diagnostic Test Characteristics for Asymptomatic MoMHRs Not Developing New
Pseudotumors for 3 Different Clinical Scenarios.
Normal Initial Ultrasound
and Initial Blood Metal
Ions b2 μg/L
Normal Initial
Ultrasound
Alone
Initial Blood Metal
Ions b2 μg/L Alone
No. of hips
(% of cohort)
50 (33) 110 (72) 62 (41)
Sensitivity 37 (29-45) 77 (69-84) 44 (35-52)
Speciﬁcity 100 (75-100) 73 (45-91) 87 (58-98)
PPV 100 (91-100) 96 (90-99) 97 (88-99)
NPV 15 (9-23) 26 (14-42) 14 (8-24)
LR+ Inﬁnity (N/A) 2.9 (1.2-6.7) 3.3 (0.9-12.1)
LR− 0.6 (0.6-0.7) 0.3 (0.2-0.4) 0.6 (0.5-0.8)
All diagnostic test characteristic values are provided as percentages with 95% conﬁdence
intervals provided in brackets.
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asymptomatic MoMHR patients with abnormal initial ultrasounds
remain under surveillance. Although worldwide authorities provide
guidance on how to follow up asymptomatic MoMHR patients [5–7],
our data suggest that this subgroup requires review within 5 years of
initial assessment. However, the exact timing of this reviewwill depend
on a number of factors including the nature of the imaging abnormality,
blood metal ion levels, and implant track record [25].
Factors associated with any progression in ﬁndings between repeat
ultrasound scans were related to blood metal ions (high initial cobalt
and chromium concentrations) and the initial ultrasound (high initial
scan grade and volume). Only high initial blood cobalt and chromium
concentrations were associated with developing new pseudotumors.
Although factors such as female gender, acetabular componentmalposi-
tion, and HR design have been observed to be risk factors for
pseudotumor formation in previous studies [26–29], they were not
associated with ultrasound progression or new pseudotumor develop-
ment in this longitudinal cohort.
The 10% of MoMHRs developing new pseudotumors all had initial
blood cobalt and/or chromium concentrations greater than 2 μg/L, as
did all 14 hips revised for symptomatic pseudotumors prior to the
repeat assessment. This ion threshold has previously been considered
the acceptable upper limit of a well-functioning MoMHR [6,30]. How-
ever, these new pseudotumors developed from all possible types of
initial ultrasound scan, that is, those that were normal (grade 1), had
bursal pathology (grade 2), and had pathological effusions (grade 3).
This suggests that all asymptomatic MoMHR patients, including those
with normal initial ultrasound scans, have a theoretical risk of develo-
ping new pseudotumors when blood metal ion concentrations are
greater than 2 μg/L. It is recommended that these patients remain
under clinical surveillance.
The optimal diagnostic test characteristics for identifying both
MoMHRs with no evidence of progression of ultrasound ﬁndings and
those not developing new pseudotumors were obtained for asymp-
tomatic MoMHRs with low initial blood cobalt and chromium levels
(b2 μg/L) and normal initial ultrasound scans (grade 1; 33% of the
current cohort). This subgroupofpatients hadvery little risk of progression
of ultrasound ﬁndings and no risk of developing new pseudotumors
within 5 years of initial assessment.
Determining the optimal diagnostic test characteristics for a screening
test depends on numerous factors, which includes the condition
being screened for [31]. The short-term outcomes after revision for
pseudotumors have largely been poor [32], which has led regulatory
authorities to issue follow-up guidance to detect problems early [5–7].
In our cohort, asymptomatic MoMHRs with low initial blood cobalt and
chromium levels (b2 μg/L) and normal initial ultrasound scans had
almost perfect speciﬁcities and PPVs for identifying MoMHRs with no
evidence of progression (Table 5), and 100% speciﬁcity and PPV for iden-
tifying hips not developing new pseudotumors within 5 years (Table 6).
Furthermore, the LR+ values were high (11.6 for no ultrasound progres-
sion and inﬁnity for not developing new pseudotumors), with a LR+ of
greater than 10 considered a large and conclusive increase in the like-
lihood of disease [33]. We therefore recommend that asymptomatic
MoMHR patients with both low initial blood metal ion levels (b2 μg/L)
and normal ultrasound scans can be safely removed from regular clinical
follow-up for the ﬁrst 5 years from initial assessment. Using ultrasound
alone or blood metal ions alone did not provide as good diagnostic test
characteristics compared to when these investigations were combined
(Tables 5 and 6). Therefore, our data provides further evidence that a
comprehensive baseline assessment in all asymptomatic MoMHR
patients using bloodmetal ions and cross-sectional imaging is important.
The ﬁnancial implications of releasing asymptomatic MoMHR
patients with normal bloodmetal ion levels (b2 μg/L) and normal ultra-
sound imaging from regular follow-up are signiﬁcant. A recent ﬁnancial
analysis of MoM hip follow-up using various worldwide protocols [10]
estimated that follow-up costs for all asymptomatic MoMHR patientsrecorded in the UK National Joint Registry (29795 hips) was £8283010
($13735495) per year when using current European guidance [6]. In
the present study, 33% of asymptomatic MoMHR patients were in the
subgroup which could be released from regular follow-up for the ﬁrst 5
years from initial assessment. Therefore, the potential cost savings
made by not reviewing this subgroup of patients for the next 5 years is
more than £13600000 ($22551520). These are huge savings, and
given that the cost of a MoM hip revision for pseudotumor has been
estimated at £10000 ($16582) per case in the UK, this would cover
1360 revision procedures.
A more conservative estimate of cost savings for asymptomatic
MoMHR follow-up can be obtained by assuming a worse-case scenario.
If all 49 MoMHRs in 36 patients from the initial cohort not recruited to
the present study were assumed to not satisfy our new recommenda-
tions for release from follow-up for 5 years (ie, assume all 49 hips had
bloodmetal ions of ≥2 μg/L and/or abnormal initial ultrasound imaging),
then 25% (50/201) of asymptomatic MoMHRs would still be eligible for
release from follow-up rather than 33% (50/152). The potential cost
savings made by not reviewing this smaller subgroup of patients for
the next 5 years still remains signiﬁcant (N £10300000, or $17079460).
This study has certain limitations. It is suspected that our ﬁndings
are not applicable to large-diameter MoM total hip arthroplasties or
MoMHR designs other than those studied here, especially the Articular
Surface Replacement (De Puy, Leeds, United Kingdom), which was
recalled in 2010 due to its high failure rate [34]. Serial ultrasound was
repeatedwithin 5 years of initial assessment, and therefore, our ﬁndings
only apply to patients undergoing repeat cross-sectional imagingwithin
this period. Further studies are needed to assess the natural history of
asymptomaticMoMHRs at extended follow-up. An experiencedmuscu-
loskeletal radiologist performed and assessed all ultrasound scans. Given
that ultrasound is operator dependent, it is possible that less experienced
radiologists would not obtain the same results. It is suspected that MRI
could be used in centerswithout adequate experience to perform and in-
terpret ultrasound imaging around MoMHRs. Finally, the deﬁnition for
pseudotumor has evolved since it was ﬁrst described in 2008 [35]. In
this study, a strict deﬁnitionwas used, and abnormalities were only clas-
siﬁed as pseudotumors if there was communication with the hip joint.
We have also clearly documented other pathology such as bursal lesions
or pathology conﬁned to the joint, with this approach recommend by
other authors [22]. Broader deﬁnitions for pseudotumors and/or classiﬁca-
tion of extra-articular lesions as pseudotumors have been used previously
[36,37]; therefore, this must be considered when interpreting our results.
Conclusions
It is proposed that all asymptomatic MoMHR patients undergo a com-
prehensive baseline assessment, which includes blood metal ions and
cross-sectional imaging. Asymptomatic MoMHR patients with normal
blood metal ion levels (b2 μg/L) and normal ultrasound imaging (33% of
the current cohort) have very little risk of progression of ultrasound
ﬁndings (2%) and no risk of developing new pseudotumors (0%) within 5
years of initial assessment. We therefore recommend that this patient sub-
group does not require repeat follow-up within 5 years of initial assess-
ment. This will result in considerable ﬁnancial savings and allow follow-
up resources to be concentrated toward those MoM hip patients requiring
further review, investigation, and/or revision surgery. Annual follow-up for
all asymptomatic MoMHR patients currently recommended by European
guidance [6] is costly and unnecessary. Longitudinal studies beyond 5
years of initial assessment are required to guide the most appropriate
follow-up regimen for asymptomatic MoMHR patients in the long term.
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